Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Pandion Therapeutics (Nasdaq: PAND) announced that CEO Rahul Kakkar will present at the 10^th Annual SVB Leerink Healthcare Conference on February 25, 2021, at 9:20 a.m. ET. The presentation will be accessible via a live webcast on the company's website, with a replay available afterward.

Pandion is focused on developing innovative therapies for autoimmune diseases, using its TALON drug design platform to create treatments like PT101, which aims to enhance regulatory T cells while minimizing proinflammatory responses.

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10^th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET.

A live webcast of the presentation will be available in the Investors and News section of Pandion Therapeutics’ website at https://www.pandiontx.com/. A replay of the webcast will be available shortly following the presentation.

About Pandion Therapeutics
Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com and engage with us on Twitter @PandionTX or on LinkedIn.

For further information, please contact:

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors:
Michelle Avery
Pandion Therapeutics
857-273-0444
investors@pandiontx.com 

FAQ

When is the SVB Leerink Healthcare Conference presentation by Pandion Therapeutics?

The presentation by Pandion Therapeutics at the SVB Leerink Healthcare Conference is scheduled for February 25, 2021, at 9:20 a.m. ET.

How can I watch the Pandion Therapeutics presentation?

You can watch the Pandion Therapeutics presentation live via webcast on their website, with a replay available shortly after.

What is the main focus of Pandion Therapeutics?

Pandion Therapeutics is focused on developing novel therapeutics to address unmet needs in patients with autoimmune diseases.

What is PT101, the lead candidate of Pandion Therapeutics?

PT101 is Pandion's lead product candidate, designed to selectively expand regulatory T cells without activating proinflammatory cells.

What is the TALON platform used by Pandion Therapeutics?

The TALON platform is a drug design and discovery platform that enables Pandion to develop immunomodulatory therapies for autoimmune conditions.